About Carbonic anhydrase 5A, mitochondrial
Carbonic anhydrase 5A, mitochondrial (CA5A) is a protein
from Homo sapiens identified by UniProt accession
P35218, 305 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Carbonic anhydrase 5A, mitochondrial |
| UniProt accession | P35218 |
| Gene | CA5A |
| Organism | Homo sapiens |
| Length | 305 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (67)
Diseases linked to this target (Open Targets).
- hyperammonemic encephalopathy due to carbonic anhydrase VA deficiency · score 0.76
- epilepsy · score 0.44
- blood protein measurement · score 0.24
- basophil percentage of leukocytes · score 0.24
- basophil percentage of granulocytes · score 0.24
- basophil count · score 0.21
- genetic disorder · score 0.19
- eosinophil count · score 0.14
- sex hormone-binding globulin measurement · score 0.09
- type 2 diabetes mellitus · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35218-F1 | alphafold | PREDICTED | 84.51 | — |
Amino-acid sequence (305 residues)
MLGRNTWKTS AFSFLVEQMW APLWSRSMRP GRWCSQRSCA WQTSNNTLHP LWTVPVSVPG GTRQSPINIQ WRDSVYDPQL KPLRVSYEAA SCLYIWNTGY LFQVEFDDAT EASGISGGPL ENHYRLKQFH FHWGAVNEGG SEHTVDGHAY PAELHLVHWN SVKYQNYKEA VVGENGLAVI GVFLKLGAHH QTLQRLVDIL PEIKHKDARA AMRPFDPSTL LPTCWDYWTY AGSLTTPPLT ESVTWIIQKE PVEVAPSQLS AFRTLLFSAL GEEEKMMVNN YRPLQPLMNR KVWASFQATN EGTRS
Explore Carbonic anhydrase 5A, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets